Loxo Oncology (LOXO) Reports Q2 Loss of $1.64, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Loxo Oncology (LOXO) Reports Q2 Loss of $1.64, Revenues Beat

Loxo Oncology Reports Second Quarter 2018 Financial Results

August 9, 2018 6:45 AM EDT

- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 -

- Updated Larotrectinib Duration of Response Data to be Reported at ESMO -

- Larotrectinib NDA PDUFA date is November 26, 2018 -

STAMFORD, Conn., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today reported second quarter 2018 financial results.

We made significant progress across our pipeline in the second quarter, said Josh... More